|
Featured Publications
Here you will find featured publications from Moores Cancer Center investigators. If you are interested in collaborating with a Moores Cancer Center investigator, please contact Ida Deichaite.
Click each investigator name to expand and view more details:
[+] David Cheresh, PhD
Professor, Vice-Chair for Research and Development
Associate Director for Translational Research, UC San Diego Moores Cancer Center
|
|
- A Src family kinase inhibitor improves survival in experimental acute liver failure associated with elevated cerebral and circulating vascular endothelial growth factor levels.
Aspinall RJ, Weis SM, Barnes L, Lutu-Fuga K, Bylund DJ, Pockros PJ, Cheresh DA.
Liver Int. 2011 Jun 7. doi: 10.1111/j.1478-3231.2011.02554.x.
- Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia.
Russell RC, Sufan RI, Zhou B, Heir P, Bunda S, Sybingco SS, Greer SN, Roche O, Heathcote SA, Chow VW, Boba LM, Richmond TD, Hickey MM, Barber DL, Cheresh DA, Simon MC, Irwin MS, Kim WY, Ohh M.
Nat Med. 2011 Jun 19;17(7):845-53. doi: 10.1038/nm.2370.
- Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression.
Schmid MC, Avraamides CJ, Dippold HC, Franco I, Foubert P, Ellies LG, Acevedo LM, Manglicmot JR, Song X, Wrasidlo W, Blair SL, Ginsberg MH, Cheresh DA, Hirsch E, Field SJ, Varner JA.
Cancer Cell. 2011 Jun 14;19(6):715-27. doi: 10.1016/j.ccr.2011.04.016.
- Targeted nanogels: a versatile platform for drug delivery to tumors.
Murphy EA, Majeti BK, Mukthavaram R, Acevedo LM, Barnes LA, Cheresh DA.
Mol Cancer Ther. 2011 Jun;10(6):972-82. Epub 2011 Apr 25.
|
[+] Judith Varner, PhD
Professor of Medicine, Division of Hematology-Oncology
UC San Diego Moores Cancer Center
|
|
- Combined blockade of integrin {alpha}4{beta}1 plus cytokines SDF-1{alpha} or IL-1{beta} potently inhibits tumor inflammation and growth.
Schmid MC, Avraamides CJ, Foubert P, Shaked Y, Kang SW, Kerbel RS, Varner JA.
Cancer Res. 2011 Sep 23. [Epub ahead of print]
- Integrins in tumor angiogenesis and lymphangiogenesis
Foubert P, Varner JA.
Methods Mol Biol. 2012;757:471-86.
- Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression.
Schmid MC, Avraamides CJ, Dippold HC, Franco I, Foubert P, Ellies LG, Acevedo LM, Manglicmot JR, Song X, Wrasidlo W, Blair SL, Ginsberg MH, Cheresh DA, Hirsch E, Field SJ, Varner JA.
Cancer Cell. 2011 Jun 14;19(6):715-27. doi: 10.1016/j.ccr.2011.04.016.
- Lymphatic endothelial heparan sulfate deficiency results in altered growth responses to vascular endothelial growth factor-C (VEGF-C).
Yin X, Johns SC, Lawrence R, Xu D, Reddi K, Bishop JR, Varner JA, Fuster MM.
J Biol Chem. 2011 Apr 29;286(17):14952-62. Epub 2011 Feb 22.
|
|
- Response to Intra-Arterial Oncolytic Virotherapy with the Herpes Virus NV1020 Evaluated by [(18)F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography.
Sze DY, Iagaru AH, Gambhir SS, De Haan HA, Reid TR.
Hum Gene Ther. 2011 Oct 14. [Epub ahead of print]
- Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer.
Tsimberidou AM, Lewis N, Reid T, Burris H, Urban P, Tan EY, Anand S, Uehara C, Kurzrock R.
Cancer Chemother Pharmacol. 2011 Apr 17. [Epub ahead of print]
- Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver.
Geevarghese SK, Geller DA, de Haan HA, Hörer M, Knoll AE, Mescheder A, Nemunaitis J, Reid TR, Sze DY, Tanabe KK, Tawfik H.
Hum Gene Ther. 2010 Sep;21(9):1119-28.
- Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval.
Breitbach CJ, Reid T, Burke J, Bell JC, Kirn DH.
Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):85-9. Epub 2010 May 15. Review.
|
|
- Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and Mcl-1.
Fecteau JF, Bharati IS, O'hayre M, Handel TM, Kipps TJ, Messmer D.
Mol Med. 2011 Oct 4. doi: 10.2119/molmed.2011.00164. [Epub ahead of print]
- ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia.
Broome HE, Rassenti LZ, Wang HY, Meyer LM, Kipps TJ.
Leuk Res. 2011 Oct;35(10):1390-4. Epub 2011 Aug 2.
- Genetic variation in phosphodiesterase (PDE) 7B in chronic lymphocytic leukemia: overview of genetic variants of cyclic nucleotide PDEs in human disease.
Peiró AM, Tang CM, Murray F, Zhang L, Brown LM, Chou D, Rassenti L, Kipps TA, Insel PA.
J Hum Genet. 2011 Sep;56(9):676-81. doi: 10.1038/jhg.2011.80. Epub 2011 Jul 28.
- IRF4 mutations in chronic lymphocytic leukemia.
Havelange V, Pekarsky Y, Nakamura T, Palamarchuk A, Alder H, Rassenti L, Kipps T, Croce CM.
Blood. 2011 Sep 8;118(10):2827-9. Epub 2011 Jul 25.
- Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells.
Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA.
Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13253-7. Epub 2011 Jul 25.
- Rituximab in chronic lymphocytic leukemia.
James DF, Kipps TJ.
Adv Ther. 2011 Jul;28(7):534-54. Epub 2011 Jul 2.
- miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia.
Visone R, Veronese A, Rassenti LZ, Balatti V, Pearl DK, Acunzo M, Volinia S, Taccioli C, Kipps TJ, Croce CM.
Blood. 2011 Sep 15;118(11):3072-9. Epub 2011 Jun 2.
|
|